

Table 2: Amniotic fluid biomarkers						
Variables	Group A: IAI (n= 41)	Group B: Non-IAI (n=54)	Biobank control samples (n=20)	p1 (A vs. B)	p2 (A vs. control)	p3 (B vs. control)
GA at amniocentesis (weeks)	28.9 (26.0-3)	27.7 (26.0-30.7)	29.2 (28.2-33.3)	0.367	0.219	0.085
EFW at ultrasound (gr)	1150.0 (864.0-1547.0)	1362.5 (1066.5 – 1741.5)	1328.0 (1025.0-1991.0)	0.141	0.051	0.263
Neonatal male sex, n(%)	26 (63.4)	32 (59.3)	12 (60.0)	0.681	0.915	0.967
EFW centile	23.0 (9.5 – 60.5)	53.5 (22.5 – 70.0)	43.5 (22.5-63.0)	0.014	0.197	0.497
Neurospecific enolase (pg/ml)	11804.55 (6213.4-21098.75)	8397.7 (3682.1-17398.3)	2393.65 (1717.05-3209.25)	0.472 ¹	0.001²	<0.001²

IAI: intraamniotic infection and/or inflammation; GA: Gestational age; EFW: Estimated fetal weight.

Continuous variables were compared using multiple lineal regression and presented as medians (25th-75th interquartile percentile). Categorical variables were compared using logistic regression and presented as number (%).

Biobank amniotic fluid samples were amniocentesis performed for reasons other than PTL/PPROM or fetal brain pathology, matched for gestational age at amniocentesis. Normal amniotic fluid results and healthy offspring were confirmed in all cases.

¹ Adjusted for centile, fetal sex, gestational age at amniocentesis and PPROM at admission.
² Adjusted for centile, fetal sex, gestational age at amniocentesis.